Herpes Simplex Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | GlaxoSmithKline, ModernaTX, Maruho Co., Bioalliance Pharma/Vectans Pharma, Novartis, Maruho Co

DelveInsight's "Herpes Simplex Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Herpes Simplex market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Herpes Simplex Market Forecast
https://www.delveinsight.com/sample-request/herpes-simplex-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Herpes Simplex Market Report:
• The Herpes Simplex market size was valued ~USD 3,159 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In April 2025, Preclinical and early clinical data unveiled at the 35th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Vienna, Austria, indicate that Assembly Biosciences' novel helicase-primase inhibitor, ABI-5366, has the potential to transform treatment for recurrent genital herpes (RGH). Unlike traditional nucleoside analogues, ABI-5366 offers the possibility of simplified oral dosing-either weekly or monthly-while demonstrating favorable pharmacokinetics, strong tissue penetration, and potent antiviral activity at nanomolar concentrations against both HSV-1 and HSV-2. These findings highlight its promise in improving treatment adherence and achieving more sustained therapeutic effects in RGH patients.
• In September 2024, GSK announced that Part II of the Phase I/II TH HSV REC-003 trial for its therapeutic herpes simplex virus (HSV) vaccine candidate, GSK3943104, failed to achieve its primary efficacy endpoint. This conclusion was drawn from an analysis of the primary objective data from the Phase II segment of the trial. Designed to offer a new therapeutic option for HSV, GSK3943104 will not be advanced to Phase III studies following the trial results.
• As per DelveInsight's analysis, the United States held the largest market share for Herpes Simplex in the 7MM, with a market size of USD 1,590 million in 2023.
• In 2023, Germany led the EU4 with the largest market size for Herpes Simplex at USD 320 million, followed by the UK at USD 282 million, while Spain had the smallest market size at USD 173 million.
• According to estimates, Japan's market size for Herpes Simplex was around USD 349 million in 2023, with expectations of growth throughout the forecast period.
• In 2023, the total diagnosed cases of Herpes Simplex in the 7MM were approximately 13,038 thousand. These cases are projected to rise over the study period from 2020 to 2034.
• According to DelveInsight's estimates, the United States accounted for approximately 38% of the total diagnosed prevalent cases of Herpes Simplex in the 7MM in 2023.
• In 2023, gender-specific cases of Herpes Simplex in the EU4 and the UK were roughly 45% male and 55% female. These cases are expected to decline over time.
• In 2023, Germany had the highest number of prevalent Herpes Simplex cases among the EU4 and the UK, followed by the UK, which recorded approximately 1,511 thousand cases.
• In 2023, recurrent herpes simplex cases in Japan showed that HSV-2 accounted for more than 67%, while HSV-1 made up 33%.
• Key Herpes Simplex Companies: Labo'Life, AiCuris Anti-infective Cures AG, GlaxoSmithKline, ModernaTX, Inc., Maruho Co., Ltd., Bioalliance Pharma/Vectans Pharma, Novartis, Maruho Co., Ltd., Beech Tree Labs, Inc., and others
• Key Herpes Simplex Therapies: 2LHERP®, Pritelivir, GSK3943104, mRNA-1608, AMENALIEF (amenamevir), SITAVIG (acyclovir), famciclovir, ASP2151, BTL TML HSV, and others
• The Herpes Simplex market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Herpes Simplex pipeline products will significantly revolutionize the Herpes Simplex market dynamics.

Herpes Simplex Overview
Herpes Simplex is a viral infection caused by the herpes simplex virus (HSV). It comes in two forms: HSV-1, which primarily causes oral herpes (cold sores), and HSV-2, which typically causes genital herpes. Both types can cause sores or blisters at the infection site and are transmitted through direct contact with the infected areas or bodily fluids. While there is no cure for herpes, antiviral treatments can help manage symptoms and reduce the risk of transmission. The virus can remain dormant in the body and reactivate periodically, causing recurrent outbreaks.

Get a Free sample for the Herpes Simplex Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/herpes-simplex-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Herpes Simplex Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Herpes Simplex Epidemiology Segmentation:
The Herpes Simplex market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Seroprevalence of HSV in the 7MM
• Total Symptomatic Cases of HSV in the 7MM
• Total Diagnosed Cases of HSV in the 7MM
• Gender-specific Diagnosed Cases of HSV in the 7MM
• Total Recurrent Cases of HSV in the 7MM

Download the report to understand which factors are driving Herpes Simplex epidemiology trends @ Herpes Simplex Epidemiology Forecast
https://www.delveinsight.com/sample-request/herpes-simplex-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Herpes Simplex Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Herpes Simplex market or expected to get launched during the study period. The analysis covers Herpes Simplex market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Herpes Simplex Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Herpes Simplex Therapies and Key Companies
• 2LHERP®: Labo'Life
• Pritelivir: AiCuris Anti-infective Cures AG
• GSK3943104: GlaxoSmithKline
• mRNA-1608: ModernaTX, Inc.
• AMENALIEF (amenamevir): Maruho Co., Ltd.
• SITAVIG (acyclovir): Bioalliance Pharma/Vectans Pharma
• famciclovir: Novartis
• ASP2151: Maruho Co., Ltd.
• BTL TML HSV: Beech Tree Labs, Inc.

Discover more about therapies set to grab major Herpes Simplex market share @ Herpes Simplex Treatment Landscape
https://www.delveinsight.com/sample-request/herpes-simplex-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Herpes Simplex Market Strengths
• The increase in healthcare expenditure in developing countries has increased access to healthcare services, including HSV treatment. This has increased the access to healthcare and surged the demand for herpes simplex virus treatment.
• The chronic and recurrent nature of HSV infections creates a sustained need for ongoing care and treatment options in the market.

Herpes Simplex Market Opportunities
• Collaboration between research institutes and healthcare sectors will immensely boost the market and its potential to make better curative therapies than existing palliative care.
• Raising public awareness for herpes simplex infections can result in an earlier diagnosis and initiation of therapy ultimately boosting the financial state.

Scope of the Herpes Simplex Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Herpes Simplex Companies: Labo'Life, AiCuris Anti-infective Cures AG, GlaxoSmithKline, ModernaTX, Inc., Maruho Co., Ltd., Bioalliance Pharma/Vectans Pharma, Novartis, Maruho Co., Ltd., Beech Tree Labs, Inc., and others
• Key Herpes Simplex Therapies: 2LHERP®, Pritelivir, GSK3943104, mRNA-1608, AMENALIEF (amenamevir), SITAVIG (acyclovir), famciclovir, ASP2151, BTL TML HSV, and others
• Herpes Simplex Therapeutic Assessment: Herpes Simplex current marketed and Herpes Simplex emerging therapies
• Herpes Simplex Market Dynamics: Herpes Simplex market drivers and Herpes Simplex market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Herpes Simplex Unmet Needs, KOL's views, Analyst's views, Herpes Simplex Market Access and Reimbursement

To know more about Herpes Simplex companies working in the treatment market, visit @ Herpes Simplex Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/herpes-simplex-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Herpes Simplex Market Report Introduction
2. Executive Summary for Herpes Simplex
3. SWOT analysis of Herpes Simplex
4. Herpes Simplex Patient Share (%) Overview at a Glance
5. Herpes Simplex Market Overview at a Glance
6. Herpes Simplex Disease Background and Overview
7. Herpes Simplex Epidemiology and Patient Population
8. Country-Specific Patient Population of Herpes Simplex
9. Herpes Simplex Current Treatment and Medical Practices
10. Herpes Simplex Unmet Needs
11. Herpes Simplex Emerging Therapies
12. Herpes Simplex Market Outlook
13. Country-Wise Herpes Simplex Market Analysis (2020-2034)
14. Herpes Simplex Market Access and Reimbursement of Therapies
15. Herpes Simplex Market Drivers
16. Herpes Simplex Market Barriers
17. Herpes Simplex Appendix
18. Herpes Simplex Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Herpes Simplex Pipeline https://www.delveinsight.com/report-store/herpes-simplex-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Herpes Simplex Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Herpes Simplex market. A detailed picture of the Herpes Simplex pipeline landscape is provided, which includes the disease overview and Herpes Simplex treatment guidelines.

Herpes Simplex Epidemiology https://www.delveinsight.com/report-store/herpes-simplex-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Herpes Simplex Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Herpes Simplex epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Dry Eye Disease Market: https://www.delveinsight.com/report-store/dry-eye-disease-market-insights
• Nonalcoholic Steatohepatitis Market: https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-market
• Female Infertility Market: https://www.delveinsight.com/report-store/female-infertility-market
• Gonorrhea Market: https://www.delveinsight.com/report-store/gonorrhea-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.